Pharmacogenomics Platforms Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PHARMACOGENOMICS PLATFORMS MARKET BY TECHNOLOGY

1. 5.1. Introduction

2. 5.2. Next-Generation Sequencing (NGS)

3. 5.3. Polymerase Chain Reaction (PCR)

4. 5.4. Microarray Technology

5. 5.5. Mass Spectrometry

6. 5.6. Others

6. PHARMACOGENOMICS PLATFORMS MARKET BY THERAPEUTIC AREA

1. 6.1. Introduction

2. 6.2. Oncology

3. 6.3. Cardiology

4. 6.4. Neurology

5. 6.5. Psychiatry

6. 6.6. Infectious Diseases

7. 6.7. Others

7. PHARMACOGENOMICS PLATFORMS MARKET BY APPLICATION

1. 7.1. Introduction

2. 7.2. Drug Discovery & Development

3. 7.3. Clinical Diagnostics

4. 7.4. Personalized Medicine

5. 7.5. Research Applications

6. 7.6. Companion Diagnostics

8. PHARMACOGENOMICS PLATFORMS MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. Thermo Fisher Scientific

2. 10.2. Illumina, Inc.

3. 10.3. F. Hoffmann-La Roche Ltd

4. 10.4. QIAGEN N.V.

5. 10.5. Agilent Technologies, Inc.

6. 10.6. GE HealthCare

7. 10.7. Abbott Laboratories

8. 10.8. Bio-Rad Laboratories

9. 10.9. Myriad Genetics, Inc.

10. 10.10. Foundation Medicine, Inc.

11. 10.11. PerkinElmer, Inc.

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations